Xenon Pharmaceuticals Inc. (XENE): Price and Financial Metrics
XENE Stock Summary
- The ratio of debt to operating expenses for Xenon Pharmaceuticals Inc is higher than it is for about only 8.32% of US stocks.
- With a year-over-year growth in debt of -79.85%, Xenon Pharmaceuticals Inc's debt growth rate surpasses merely 2.97% of about US stocks.
- Revenue growth over the past 12 months for Xenon Pharmaceuticals Inc comes in at 371.02%, a number that bests 98.13% of the US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to Xenon Pharmaceuticals Inc, a group of peers worth examining would be ATHX, MGNX, CRBP, RCUS, and NTLA.
- Visit XENE's SEC page to see the company's official filings. To visit the company's web site, go to www.xenon-pharma.com.
XENE Stock Price Chart Interactive Chart >
XENE Price/Volume Stats
| Current price | $19.04 | 52-week high | $21.94 |
| Prev. close | $18.18 | 52-week low | $9.32 |
| Day low | $17.99 | Volume | 764,016 |
| Day high | $19.90 | Avg. volume | 190,936 |
| 50-day MA | $18.20 | Dividend yield | N/A |
| 200-day MA | $13.81 | Market Cap | 681.80M |
Xenon Pharmaceuticals Inc. (XENE) Company Bio
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing differentiated therapeutics for orphan indications in Canada. The company was founded in 1996 and is based in Burnaby, Canada.
Latest XENE News From Around the Web
Below are the latest news stories about Xenon Pharmaceuticals Inc that investors may wish to consider to help them evaluate XENE as an investment opportunity.
How Many Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Do Institutions Own?A look at the shareholders of Xenon Pharmaceuticals Inc. ( NASDAQ:XENE ) can tell us which group is most powerful... |
Xenon Pharmaceuticals to Participate in Upcoming Investor ConferencesBURNABY, British Columbia, April 08, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that members of its executive management team will present a corporate overview and participate in the following virtual investor conferences: 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, 2021 at 10:15 am ET. The live webcast of the fireside chat can be accessed here.2021 Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 3:00 pm ET. The live webcast of the company presentation can be accessed here. Details on company presentations and the links to webcasts can be found on the “Investors” section of Xenon’s website at http://investor.xenon-pharma.com. When available, we... |
Xenon Pharmaceuticals to Participate in the Stifel 3rd Annual CNS DayBURNABY, British Columbia, March 29, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that the Company will participate in a fireside chat at the following virtual investor conference: Stifel 3rd Annual CNS Day (fireside chat presentation) on Wednesday, March 31, 2021 at 1:00 pm ET The presentation will be webcast live and archived on the “Investors” section of Xenon's website at http://investor.xenon-pharma.com. The above listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurolog... |
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Tops Revenue EstimatesXenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 15.00% and 47.14%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock? |
Recap: Xenon Pharmaceuticals Q4 EarningsShares of Xenon Pharmaceuticals (NASDAQ:XENE) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 17.07% over the past year to ($0.34), which beat the estimate of ($0.40). Revenue of $5,150,000 up by 54.70% from the same period last year, which beat the estimate of $3,220,000. Looking Ahead Xenon Pharmaceuticals hasn't issued any earnings guidance for the time being. Revenue guidance hasn't been issued by the company for now. Details Of The Call Date: Mar 01, 2021 View more earnings on XENE Time: 04:30 PM ET Webcast URL: https://edge.media-server.com/mmc/p/xocwzofr Technicals 52-week high: $20.73 52-week low: $7.00 Price action over last quarter: Up 63.35% Company Overview Xenon Pharmaceuticals Inc is a clinical-stage b... |
XENE Price Returns
| 1-mo | 8.74% |
| 3-mo | 19.22% |
| 6-mo | 77.61% |
| 1-year | 56.97% |
| 3-year | 271.51% |
| 5-year | 150.20% |
| YTD | 23.80% |
| 2020 | 17.32% |
| 2019 | 107.77% |
| 2018 | 123.36% |
| 2017 | -63.31% |
| 2016 | -4.23% |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...